Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05039892 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholangiocarcinoma,Adult

Interventions

DRUG: 3D185

Sponsor

3D Medicines (Beijing) Co., Ltd.